IGF2BP1 Antibodies

Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)

RNA-binding factor that recruits target transcripts into cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage.

It also modulates the speed and location where target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation. Plays a direct role in the transport and translation of transcripts necessary for axonal regeneration in adult sensory neurons (By similarity).

Gene Information

Human
Gene Name:	IGF2BP1
Uniprot:	Q9NZI8
Entrez:	10642

Family

Belongs to:
RRM IMP/VICKZ family

Alternative Names

Coding region determinant-binding protein; CRD-BP; CRDBPIGF-II mRNA-binding protein 1; IGF II mRNA binding protein 1; IMP1; IMP-1ZBP-1; insulin-like growth factor 2 mRNA binding protein 1; insulin-like growth factor 2 mRNA-binding protein 1; VICKZ family member 1; VICKZ1; ZBP1IGF2 mRNA-binding protein 1; Zip code-binding protein 1; Zipcode-binding protein 1

Molecular Weight

Mass (kDA):
63.481 kDA

Genomic Context

Human
Location:	17q21.32
Sequence:	17; NC_000017.11 (48997385..49056145)

Tissue Specificity

Mainly expressed in the embryo, including in fetal liver, fetal lung, fetal kidney, fetal thymus (at protein level). Also expressed follicles of ovary, as well as in gonocytes of testis, spermatogonia, semen, oocytes and placenta (at protein level). Expressed in various cancers, including testis and lung cancers (at protein level), as well as kidney, prostate and trachea cancers.

Subcellular Localizations

Nucleus. Cytoplasm. Cytoplasm, perinuclear region. Cell projection, lamellipodium. Cell projection, dendrite. Cell projection, dendritic spine. Cell projection, growth cone. Cell projection, filopodium. Cell projection, axon. In the nucleus, located in discrete foci, coinciding with the sites of ACTB transcription (By similarity). In the cytoplasm, localizes in cytoplasmic mRNP granules. Colocalizes with microtubules in growth cone filopodia and along neurites in neuronal cells (By similarity). Cytoplasmic colocalization with ACTB mRNA is partially lost at the cell periphery, suggesting releas

Diseases

• Malignant Neoplasms
• Neoplasms
• Neoplasm Metastasis
• Cell Transformation, Neoplastic
• Malignant Paraganglionic Neoplasm
• Tissue Adhesions
• Mutation Abnormality
• Oncogene Activation Process
• Intracranial Neoplasm
• Endometrial Polyp
• Malignant Neoplasm Of Lung
• Immunologic Deficiency Syndromes

• Myopathy
• Metabolic Syndrome X
• Exanthema
• Meningeal Neoplasms
• Meningioma
• Leukaemia Recurrent
• Congenital Absence

Interacting Proteins

• Cbx7
• STAU1

Pathways

• Translation
• Cell Migration
• Dna Methylation
• Localization
• Methylation
• Transport
• Cell Adhesion
• Cell Proliferation
• Cell Aging
• Aging
• Histone Modification
• Virulence
• Senescence

• Tooth Eruption
• Organ Development
• Mrna Stabilization
• Vulval Development
• Menarche
• Wound Healing
• Iron-sulfur Cluster Assembly

PTMs

• Methylation

• Phosphorylation

• Cleavage

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/IGF2BP1

Best Uses Of The IGF2BP1 Marker

There are several benefits of using the IGF2BP1 marker to aid in your research. You can submit your results for species-specific samples, applications, and even get product credits. Boster scientists can apply the markers to various scientific researches from all over the world. In this article, we'll explore the benefits of this mRNA. After reading this article, you'll be well-equipped to use this biomarker to further your research.

IGF2BP1

IGF2BP1 is a cancer-specific gene. Researchers have identified that it is significantly elevated in ovarian and cervical cancer. Interestingly, IGF2BP1 is inversely correlated with two other RNA molecules, miR-140-5p and miR-124-3p, and researchers have suggested that they may act as inhibitors of tumor cell proliferation, migration, and growth.

The study also found that the expression of IGF2BP1 is correlated with the Bcl-2 antiapoptotic protein. The gene is also implicated in the development of AML and contributes to poor prognosis. It may also be used to target cancer therapeutics. Ultimately, this marker has many uses. Using it to investigate cancer cells could be a valuable way to detect tumors early and target them early.

Several small molecule inhibitors target the IGF2BP1 mRNA and block the binding of IGF2BP1 to the corresponding mRNA. This inhibitor, BTYNB, inhibits cell proliferation of IGF2BP1-positive cancer cells, but has minimal impact on cancer cells that are not IGF2BP1-positive. The inhibitors inhibit tumor-related mRNA stabilizing proteins and upstream ncRNAs.

The protein m6A is the most abundant epigenetic modification of mRNA in eukaryotes. Dysregulation of m6A-associated proteins plays a crucial role in the progression of disease. The gene IGF2BP3 regulates is expressed in acute myeloid leukemia (AML), a disease with poor prognosis and genetic risk. Knocking out the protein impairs AML cells' ability to proliferate and self-renew.

Methylation of IGF2BP1 causes a change in gene expression in tumor cells, which inhibits their growth and metastases. Alternatively, methylation of IGF2BP1 inhibits the expression of cancer-related mRNAs. However, the mechanism that drives the methylation of IGF2BP1 remains unclear. However, there are some promising uses of this gene in cancer research.

Its target mRNAs

The IGF2BP1 gene plays an important role in the regulation of actin dynamics in primary neurons and tumor-derived cells. This gene regulates b-actin mRNA levels and facilitates their localization. It has been proposed that IGF2BP1 can regulate the directed protrusion of cells in response to external guidance cues. Targeted mRNAs of IGF2BP1 are important for understanding the mechanisms involved in the regulation of cell protrusion.

IGF2BP1 is a member of the IGF2BP gene family, and has a high promoter methylation level. It inhibits b-catenin binding to its promoter, which is important for cancer cell proliferation and migration. It is thought that selective methylation of mRNAs containing m6A is the result of competitive interactions with other m6A-binding proteins. Furthermore, YTHDFs and mRNA-binding proteins both read the same m6A-containing regions, but they determine different fates.

In the HT-144 cell line, IGF2BP1 knockdown reduced CDh2 expression and inhibited the formation of cell-cell contacts. IGF2BP1 expression was decreased without affecting cell-cell contacts, but increased ACTB protein levels. This suggests that transcriptional EMT-drivers play a role in controlling IGF2BP1 expression.

IGF2BP1 is overexpressed in human and mouse breast tumor cells. It promotes tumor cell migration and invasion. In addition, IGF2BP1 depletion inhibited the migration and invasion of rat and human breast cancer cells. It has also been suggested that IGF2BP1 may suppress chemotaxis and apoptosis in cancer cells.

The IGF2BP1 gene interferes with the degradation of LEF1 mRNA. The gene influences LEF1 expression and mRNA stability, while IGF2BP3 and IGF2BP2 have minimal effect on the LEF1 mRNA. While knockdown of IGF2BP1 inhibits tumor growth, it does not affect the stability of LEF1 mRNA.

Its inhibitor

The efficacy of IGF2BP1 inhibition has been demonstrated in several cell lines, including HCCLM3 and HepG2 cells. The inhibition of IGF2BP1 inhibits both mRNA and protein levels. This compound has a wide range of possible applications in a wide range of cancers. In addition to its anti-cancer effects, it also shows promising potential as a therapeutic agent.

The IGF2BP1 enzyme is overexpressed in several cancers, including retinoblastoma and choriocarcinoma. In addition to promoting tumor cell proliferation, IGF2BP1 inhibits migration and invasion. Its target mRNAs are not affected by depletion of RSK2 or PPME, but their function in tumorigenesis is inhibited by inhibition of IGF2BP1.

RNA binding proteins regulate the expression of genes and regulate gene expression. IGF2BP1 is known to bind to mRNAs with the m6A sequence. Mutations in this gene are associated with poor prognosis and decreased survival. The inhibition of IGF2BP1 by molecules with specific inhibitory activity has potential as a therapeutic agent. The molecule inhibits mRNA binding and the downstream signalling of Kras. It also inhibits wound healing and growth in soft agar.

The reduction of ACTB in human cells is associated with improved cancer cell survival. The reduced level of ACTB contributes to increased cell adhesion and migration velocity. Reduced ACTB levels also decrease IGF2BP1 expression and methylation of the promoter region of IGF2BP1. These inhibitors also affect downstream cellular pathways. It is still unclear what the driving factors are for IGF2BP1 expression.

In addition to its anti-cancer activity, IGF2BP3 is involved in the growth of cancer cells. In cancer cells, it suppresses apoptosis and inhibits tumor cell migration. This means that it has potential as a cancer therapeutic. The development of a treatment for this protein could help patients with leukemia. In addition, IGF2BP3 inhibits Akt signaling, a crucial pathway in cisplatin resistance.

Clinical applications

The IGF2BP1 gene has multiple clinical applications. It acts as an oncogene and is highly expressed in ovarian cancer cells. It promotes tumor cell proliferation and migration and impairs mRNA decay. Several reports suggest that IGF2BP1 is an important prognostic marker in ovarian cancer. The protein is also associated with neuroblastic tumors. But the mechanisms that drive its expression are not entirely clear.

Despite these promising results, further studies are necessary to assess whether this marker is a reliable tool for identifying atypical follicular thyroid cancer. In this case, it may provide the first definitive positive marker for detecting ATC. The IGF2BP1 gene is expressed robustly in ATC. Clinical trials of the new blood test will evaluate its potential as a diagnostic tool in ATC.

The IGF2BP1 gene is expressed in several high-grade malignancies, including T cell lymphoma and lung adenocarcinoma. However, this gene is often expressed de novo in some of these high-grade tumors. Therefore, IGF2BP1 immunostaining could lead to false-positive results. However, there are established markers of ATC (cytokeratins and thyroid-specific transcription factor PAX8) that may help differentiate the disease from other neoplasms.

The expression of IGF2BP1 in cells is measured in both HeLa and C33A cell lines. The effects of siIGF2BP1 on cell proliferation, migration, and invasion are analyzed using CCK8 assays. This is an excellent test for monitoring disease progression in various clinical settings. But it is also useful in assessing the efficacy of therapeutic interventions. Thus, IGF2BP1 is a valuable tool in cancer research.

Its potential as a drug target

Using multiple methods for characterization of proteins, researchers discovered 15 candidates with anti-targets in the host. These candidates were categorized as antigen-specific, cellular, or broad spectrum, druggable, and enriched with functional and cellular information. Additionally, six of them were homologous to more than 75 different pathogens and are potentially good candidates for vaccines. Once validated, these targets could be further used to discover novel therapeutic compounds.

The Tmod protein contains an activator that can awaken T cells in response to an antigen. Antigens like CEA and MSLN are expressed on various tumor cells and healthy tissues. To combat the immune response, A2 Bio based its targeting strategy on loss of heterozygosity, a genetic mutation where one of the parents of a gene has been altered. This mutation is common in tumor cells, and could serve as a target for future therapies.